Advances in synthetic siRNA delivery.

N. Manjunath, Derek M. Dykxhoorn

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


The application of RNA interference-based gene silencing technologies has the potential to treat a variety of illness. Preclinical studies and some early clinical trials have already demonstrated the utility of small interfering RNAs (siRNAs) as a potential novel therapy for the treatment of cancer, viral infections, as well as a wide range of additional diseases. To be effective, an siRNA must be taken up by specific cells, enter the cytoplasm, and be loaded onto the Argonaute protein, the catalytic core of the RNA induced silencing complex (RISC) to direct the cleavage of the homologous transcripts. To meet this need, a variety of novel siRNA delivery strategies have been developed. As our understanding of the molecular mechanisms underlying the RNAi pathway has increased so has the ability to rationally design effective silencing and delivery strategies. This review will examine the latest advances in non-viral delivery of siRNA, with special reference to targeted siRNA delivery to specific target tissues and cell types in vivo in preclinical animal models.

Original languageEnglish (US)
Pages (from-to)418-430
Number of pages13
JournalDiscovery Medicine
Issue number48
StatePublished - May 2010
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Advances in synthetic siRNA delivery.'. Together they form a unique fingerprint.

Cite this